POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER).
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining cellular membrane potential, nerve impulse transmission, muscle contraction, and acid-base balance. Dextrose 5% provides a source of calories and water for hydration.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis and the citric acid cycle. |
| Excretion | Renal: >90% as potassium ions; feces: <10%; negligible biliary excretion. |
| Half-life | Terminal half-life approximately 0.5-1 hour for rapid distribution; clinical context: potassium is primarily intracellular, and serum half-life reflects redistribution rather than elimination. In renal impairment, half-life may prolong due to decreased excretion. |
| Protein binding | Minimal; approximately 0-10% bound to albumin; most potassium is free in plasma. |
| Volume of Distribution | Approximately 0.5-0.7 L/kg (total body water distribution); clinical meaning: potassium distributes primarily into intracellular space (98%), with Vd reflecting total body water. Higher Vd indicates larger intracellular stores. |
| Bioavailability | Oral: 85-100% (well absorbed); Intravenous: 100%. |
| Onset of Action | Intravenous: immediate (within seconds to minutes) for cardiac effects; oral: 30-60 minutes for serum potassium elevation. |
| Duration of Action | Intravenous: 2-4 hours for acute effects; oral: 4-6 hours. Continuous infusion maintains effect. Note: Duration depends on renal function and total body potassium deficit. |
10-20 mEq/hour intravenously, not to exceed 20 mEq/hour; maximum 200 mEq/day; adjust based on serum potassium levels.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: administer with caution, maximum 100 mEq/day. GFR <30 mL/min: avoid use or reduce dose to 50% of standard; monitor potassium closely. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose to 50-75% of standard, but evidence limited; monitor potassium levels. |
| Pediatric use | IV: 0.5-1 mEq/kg/dose, up to 20 mEq/dose, infused at 0.3-0.5 mEq/kg/hour; maximum 1 mEq/kg/hour. Adjust based on deficiency and monitoring. |
| Geriatric use | Initiate at low end of dosing range (5-10 mEq/hour IV); maximum 100 mEq/day; monitor renal function and potassium levels frequently due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Breastfeeding | Potassium chloride is endogenous and excreted into breast milk in small amounts. The M/P ratio is approximately 0.9. At maternal therapeutic doses, no adverse effects in breastfed infants are anticipated. Use is considered compatible with breastfeeding. |
| Teratogenic Risk | Potassium chloride is a physiologic electrolyte. No teratogenic effects are expected. There is no evidence of fetal risk at therapeutic doses; however, maternal hyperkalemia may cause fetal arrhythmias. In first trimester, no known structural teratogenicity. In second and third trimesters, maternal potassium imbalance can affect fetal cardiac conduction. |
■ FDA Black Box Warning
Concentrated potassium chloride solutions (≥2 mEq/mL) must be diluted before administration. Rapid intravenous administration of undiluted potassium chloride can cause fatal hyperkalemia and cardiac arrest.
| Serious Effects |
["Hyperkalemia","Severe renal impairment with oliguria or anuria","Concurrent use with potassium-sparing diuretics or ACE inhibitors (relative)","Adams-Stokes syndrome","Severe hemolytic reactions"]
| Precautions | ["Monitor serum potassium, glucose, and electrolyte levels frequently","Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia","Adjust rate of infusion based on clinical status and laboratory values","Avoid extravasation as may cause tissue necrosis"] |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium levels, ECG for cardiac effects, and renal function. In pregnancy, monitor fetal heart rate during infusion due to risk of maternal hyperkalemia-induced fetal bradycardia. Assess for signs of hyperkalemia (e.g., muscle weakness, paresthesias). |
| Fertility Effects | No known adverse effects on fertility. Potassium chloride is essential for cellular function; imbalances may affect reproductive physiology, but therapeutic use is not associated with fertility impairment. |